Asset Details
Do you wish to reserve the book?
Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Do you wish to request the book?
Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
2017
Overview
Background
Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair Cross-Complementation Group 1) in prostate cancer progression.
Methods
To better understand the impact of ERCC1 protein expression in human prostate cancer, a preexisting tissue microarray (TMA) containing more than 12,000 prostate cancer specimens was analyzed by immunohistochemistry and data were compared with tumor phenotype, PSA recurrence and several of the most common genomic alterations (
TMPRSS2:ERG
fusions: deletions of
PTEN
, 6q, 5q, 3p).
Results
ERCC1 staining was seen in 64.7% of 10,436 interpretable tissues and was considered weak in 37.1%, moderate in 22.6% and strong in 5% of tumors. High-level ERCC1 staining was linked to advanced pT stage, high Gleason grade, positive lymph nodes, high pre-operative serum PSA, and positive surgical margin status (
p
< 0.0001 each). High ERCC1 expression was strongly associated with an elevated risk of PSA recurrence (
p
< 0.0001). This was independent of established prognostic features. A subgroup analysis of cancers defined by comparable quantitative Gleason grades revealed that the prognostic impact was mostly driven by low-grade tumors with a Gleason 3 + 3 or 3 + 4 (Gleason 4: ≤5%). High ERCC1 expression was strongly associated with the presence of genomic alterations and expression levels increased with the number of deletions present in the tumor. These latter data suggest a functional relationship of ERCC1 expression with genomic instability.
Conclusion
The results of our study demonstrate that expression of ERCC1 - a potential surrogate for genomic instability - is an independent prognostic marker in prostate cancer with particular importance in low-grade tumors.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antigens
/ Biomedical and Life Sciences
/ DNA
/ DNA-Binding Proteins - metabolism
/ ERCC1
/ Genes
/ Health Promotion and Disease Prevention
/ Humans
/ Male
/ Oncogene Proteins, Fusion - genetics
/ Oncogene Proteins, Fusion - metabolism
/ Oncology
/ Prostate-Specific Antigen - blood
/ Prostatic Neoplasms - genetics
/ Prostatic Neoplasms - metabolism
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - pathology
/ Tumors
